Apple’s iWatch Potential, GlaxoSmithKline Fields Drug Bid, and 3 More Hot Stocks
Apple (NASDAQ:AAPL): Jefferies’ analyst Peter Misek believes that the speculated iWatch will be more of a hobby line for Apple, but not a full-blown product line for the company. Misek keeps a broad price range of $50-$300 on the device — presumably available in different versions. However, he remains cautious since he does not believe that the greater market will become fully accepting of smart watches.
GlaxoSmithKline (NYSE:GSK): The British pharmaceutical giant has received an offer from South Africa’s Aspen Pharmacare for its thrombosis drug brands Arixtra and Fraxiparine, which could be worth as much as 700 million pounds — twice this year’s anticipated sales of the treatments, which have been steadily declining as the drugs age. Were a deal to materialize, about 1,000 Glaxo workers would move to South Africa.
ACADIA Pharmaceuticals (NASDAQ:ACAD): Shares are down slightly after the company announced that data from a Phase III trial of pimavanserin for Parkinsons Disease Psychosis indicates that the treatment is well-tolerated and effective when administered long-term.
Oracle (NASDAQ:ORCL): RBC Capital’s Matthew Hedberg argues that Oracle can support a doubling of its current dividend, which stands at $0.06 per share — a 0.7 percent yield. The analyst points out that Oracle only paid out 9 percent of its free cash flow in 2012, a third of a peer group average of 27 percent. On the other hand, buybacks took up 45 percent of free cash flow, a little above the peer group’s average of 41 percent.
Zillow (NASDAQ:Z): The real estate site is stepping up its game in the online property market, by launching its first TV spot aimed at helping young families find their homes — not houses. The touching ad is apart Zillow’s “Find Your Way Home” ad campaign, and will be shown on CNN, USA, A&E, and other cable networks. Zillow sales and marketing spending rose 138 percent year over year in Q1, to $19.8 million.
Don’t Miss: Is Samsung Not the Apple Rival It’s Billed As?